The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Nano-biosensors to detect beta-amyloid for Alzheimer's disease management
Open accessAbstract
Beta-amyloid (β-A) peptides are potential biomarkers to monitor Alzheimer’s diseases (AD) for diagnostic purposes. Increased β-A level is neurotoxic and induces oxidative stress in brain resulting in neurodegeneration and causes dementia. As of now, no sensitive and inexpensive method is available for β-A detection under physiological and pathological conditions. Although, available methods such as neuroimaging, enzyme-linked immunosorbent assay (ELISA), and polymerase chain reaction (PCR) detect β-A, but they are not yet extended at point-of-care (POC) due to sophisticated equipments, need of high expertise, complicated operations, and challenge of low detection limit. Recently, β-A antibody based electrochemical immuno-sensing approach has been explored to detect β-A at pM levels within 30–40 minutes compared to 6–8 hours of ELISA test. The introduction of nano-enabling electrochemical sensing technology could enable rapid detection of β-A at POC and may facilitate fast personalized health care delivery. This review explores recent advancements in nano-enabling electrochemical β-A sensing technologies towards POC application to AD management. These analytical tools can serve as an analytical tool for AD management program to obtain bio-informatics needed to optimize therapeutics for neurodegenerative diseases diagnosis management
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Hypothesis of β-A to monitor Alzheimer’s Diseases The role of β-A peptide for AD monitoring has been investigated and well-accepted (Claeysen et al. 2015; Haass and Selkoe 2007; LaFerla et al. 2007).”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · cited 6×
“Recently, soluble markers for AD detection are also explored for disease monitoring (Nestor et al. 2004) like total tau protein or β-A levels in CSF or plasma samples (Georganopoulou et al. 2005).”
InfluentialElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390
Recent advances in cortisol sensing technologies for point-of-care application
Kaushik, A., Vasudev, A., Arya, S. K., Pasha, S. K., & Bhansali, S. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.09.060 · Cited by 316
Self-citationInnovative diagnostic tools for early detection of Alzheimer's disease
Laske, C., Sohrabi, H. R., Frost, S. M., López-de-Ipiña, K., Garrard, P., Buscema, M., Dauwels, J., Soekadar, S. R., Mueller, S., Linnemann, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.004 · Cited by 316
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients
Green, D. A., Masliah, E., Vinters, H. V., Beizai, P., Moore, D. J., & Achim, C. L. (2005) · AIDS · doi:10.1097/01.aids.0000161770.06158.5c · Cited by 299
Multimodal Nanoprobes to Target Cerebrovascular Amyloid in Alzheimer’s Disease Brain
Jaruszewski, K. M., Curran, G. L., Swaminathan, S. K., Rosenberg, J. T., Grant, S. C., Ramakrishnan, S., Lowe, V. J., Poduslo, J. F., & Kandimalla, K. K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.075 · Cited by 64
Probing copper/tau protein interactions electrochemically
Martic, S., Rains, M. K., & Kraatz, H.-B. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.07.015 · Cited by 60
Cited by
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Self-citationJain, S., Nehra, M., Kumar, R., Dilbaghi, N., Hu, T., Kumar, S., Kaushik, A., & Li, C.-Z. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113074 · Cited by 357
Self-citationPersonalized nanomedicine for CNS diseases
Kaushik, A., Jayant, R. D., Bhardwaj, V., & Nair, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.010 · Cited by 95
Self-citation
Metadata
- Authors
- Kaushik, A., Jayant, R. D., Tiwari, S., Vashist, A., & Nair, M.
- Venue
- Biosensors and Bioelectronics
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 80
- Pages
- 273-287
- ISSN
- 0956-5663 (ISSN-L)
- OpenAlex
- W2291981256
- Cited by
- 165
- References
- 12
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.